Literature DB >> 18984611

Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis.

J H W Distler1, A Akhmetshina, G Schett, O Distler.   

Abstract

Activation of the immune system and increased synthesis of extracellular matrix proteins by fibroblasts are hallmarks in the pathogenesis of SSc. The molecular mechanisms underlying the infiltration of inflammatory cells into the skin and the subsequent activation of fibroblasts are still largely unknown. Chemokines are a family of small molecules that are classified according to the position of the NH(2)-terminal cysteine motif. Recent data indicate that chemokines and in particular two members of the subfamily of monocyte chemoattractant proteins, MCP-1 (CCL-2) and MCP-3 (CCL-7), might be involved in the pathogenesis of SSc. MCP-1 and -3 are overexpressed by SSc fibroblasts and in skin lesions from SSc patients compared to healthy controls. MCP-1 and -3 are chemotactic for inflammatory cells and stimulate their migration into the skin. In addition to their pro-inflammatory effects, MCP-1 and -3 contribute to tissue fibrosis by activating the synthesis of extracellular matrix proteins in SSc fibroblasts. Therapeutic strategies targeting MCP-1 have revealed promising results in several animal models of SSc. Antagonists against the receptor CCR2 are currently tested in clinical trials of a variety of diseases and also represent interesting candidates for target-directed therapy in SSc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18984611     DOI: 10.1093/rheumatology/ken401

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  14 in total

1.  Membrane array and multiplex bead analysis of tear cytokines in systemic sclerosis.

Authors:  Aniko Rentka; Jolan Harsfalvi; Gabriella Szucs; Zoltan Szekanecz; Peter Szodoray; Krisztina Koroskenyi; Adam Kemeny-Beke
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

2.  Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis.

Authors:  Minoru Hasegawa; Manabu Fujimoto; Takashi Matsushita; Yasuhito Hamaguchi; Kazuhiko Takehara; Shinichi Sato
Journal:  Clin Rheumatol       Date:  2010-11-04       Impact factor: 2.980

Review 3.  Is there evidence for vasculitis in systemic sclerosis?

Authors:  Lesley Ann Saketkoo; Oliver Distler
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

Review 4.  Targeted therapies for systemic sclerosis.

Authors:  Christopher P Denton; Voon H Ong
Journal:  Nat Rev Rheumatol       Date:  2013-04-09       Impact factor: 20.543

5.  Establishment of a humanized animal model of systemic sclerosis in which T helper-17 cells from patients with systemic sclerosis infiltrate and cause fibrosis in the lungs and skin.

Authors:  Min-Jung Park; Youngjae Park; Mi-La Cho; Sung-Hwan Park; Jeong Won Choi; Jin-Ah Baek; Ha Yeon Jeong; Hyun Sik Na; Young-Mee Moon
Journal:  Exp Mol Med       Date:  2022-09-29       Impact factor: 12.153

Review 6.  Current perspectives on the role of CD8+ T cells in systemic sclerosis.

Authors:  Patrizia Fuschiotti
Journal:  Immunol Lett       Date:  2017-10-05       Impact factor: 3.685

Review 7.  Chemokines in rheumatic diseases: pathogenic role and therapeutic implications.

Authors:  Yoshishige Miyabe; Jeffrey Lian; Chie Miyabe; Andrew D Luster
Journal:  Nat Rev Rheumatol       Date:  2019-11-08       Impact factor: 20.543

8.  Fli1 Downregulation in Scleroderma Myeloid Cells Has Profibrotic and Proinflammatory Effects.

Authors:  Andreea M Bujor; Fatima El Adili; Arshi Parvez; Grace Marden; Maria Trojanowska
Journal:  Front Immunol       Date:  2020-05-19       Impact factor: 7.561

9.  Enhanced chemokine-receptor expression, function, and signaling in healthy African American and scleroderma-patient monocytes are regulated by caveolin-1.

Authors:  Rebecca Lee; Charles Reese; Beth Perry; Jonathan Heywood; Michael Bonner; Marina Zemskova; Richard M Silver; Stanley Hoffman; Elena Tourkina
Journal:  Fibrogenesis Tissue Repair       Date:  2015-06-20

10.  Versican is upregulated in circulating monocytes in patients with systemic sclerosis and amplifies a CCL2-mediated pathogenic loop.

Authors:  Ayako Masuda; Hidekata Yasuoka; Takashi Satoh; Yuka Okazaki; Yukie Yamaguchi; Masataka Kuwana
Journal:  Arthritis Res Ther       Date:  2013-07-11       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.